In 2020, Lei Sun et al
Instead, the USPSTF came down on the side of intensive behavioral interventions, not obesity medications
We searched the primary literature in PubMed, Embase and SciELO from inception to June 2025, using the terms diabetes, type 2 diabetes mellitus, glucagon-like peptide-1, L-cell, metabolic surgery, jejunostomy, GLP-1 receptor agonists as well as their combinations
Feed it, turn lights on/off, play with it, give it medicine, flush after its used the bathroom, check its health and discipline your Tamagotchi if he bothers you when hes happy, fed and all cleaned up
Why People Consider Microdosing GLP-1 Medications Several factors drive interest in microdosing these powerful medications
That timing helps align the therapy with the moments of highest metabolic demand